Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Accured Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Kezar Life Sciences (KZR) Shares Issued (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Shares Issued for 5 consecutive years, with $30000.0 as the latest value for Q4 2025.

For Q4 2025, Shares Issued changed N/A year-over-year to $30000.0; the TTM value through Dec 2025 reached $131.7 million, changed N/A, while the annual FY2025 figure was $65000.0, 36.89% down from the prior year.
Shares Issued hit $30000.0 in Q4 2025 for Kezar Life Sciences, down from $131.7 million in the prior quarter.
Across five years, Shares Issued topped out at $131.7 million in Q2 2023 and bottomed at $30000.0 in Q4 2025.
Average Shares Issued over 5 years is $34.0 million, with a median of $394000.0 recorded in 2021.
On a YoY basis, Shares Issued climbed as much as 27524.11% in 2022 and fell as far as 84.05% in 2022.
Kezar Life Sciences' Shares Issued stood at $580000.0 in 2021, then dropped by 12.76% to $506000.0 in 2022, then soared by 25927.67% to $131.7 million in 2023, then changed by 0.0% to $131.7 million in 2024, then crashed by 99.98% to $30000.0 in 2025.
According to Business Quant data, Shares Issued over the past three periods came in at $30000.0, $131.7 million, and $131.7 million for Q4 2025, Q2 2024, and Q4 2023 respectively.